Skip to main content
. 2021 Mar 16;41(5):459–468. doi: 10.1007/s40261-021-01023-8

Fig. 4.

Fig. 4

Cost-effectiveness price threshold analysis. Populations included are a CAD or PAD, b PAD, c CAD, d CAD and PAD, e CAD with CKD, and f CAD with HF. CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, QALY quality-adjusted life-year